Charles River Laboratories International (MIL:1CRL) LT-Debt-to-Total-Asset: 0.40 (As of Mar. 2026)

What is Charles River Laboratories International LT-Debt-to-Total-Asset?

Charles River Laboratories International MIL:1CRL 70 LT-Debt-to-Total-Asset is 0.40 as of Mar. 2026. GuruFocus rates MIL:1CRL with a GF Score™ of 70/100 and a GF Value™ of €121.29. The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Charles River Laboratories International's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.40.

Charles River Laboratories International's long-term debt to total assets ratio increased from Mar. 2025 (0.39) to Mar. 2026 (0.40). It may suggest that Charles River Laboratories International is progressively becoming more dependent on debt to grow their business.

Charles River Laboratories International (MIL:1CRL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Charles River Laboratories International LT-Debt-to-Total-Asset Related Terms

Charles River Laboratories International LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International LT-Debt-to-Total-Asset Chart

Charles River Laboratories International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.42

0.41

0.37

0.36

Charles River Laboratories International Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.39	0.37	0.35	0.36	0.40

70GF Score

Charles River Laboratories International Inc MIL:1CRL

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Charles River Laboratories International LT-Debt-to-Total-Asset Calculation

Charles River Laboratories International's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	2195.128	/	6093.65
	=	0.36

Charles River Laboratories International's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	2643.653	/	6686.716
	=	0.40

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.40 mean?

Charles River Laboratories International (MIL:1CRL) has a LT-Debt-to-Total-Asset of 0.40 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Charles River Laboratories International and its competitors.

Is Charles River Laboratories International's LT-Debt-to-Total-Asset too high?

Charles River Laboratories International's current LT-Debt-to-Total-Asset is 0.40. Overall, Charles River Laboratories International has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.

How does Charles River Laboratories International's LT-Debt-to-Total-Asset compare to RVTY and QGEN?

Charles River Laboratories International's LT-Debt-to-Total-Asset of 0.40 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?

A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Charles River Laboratories International and its competitors. Charles River Laboratories International's current LT-Debt-to-Total-Asset is 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Charles River Laboratories International stock overvalued right now?

Charles River Laboratories International (MIL:1CRL) has a current LT-Debt-to-Total-Asset of 0.40. The stock's GF Value™ is €121.29, compared to a current price of €143.90 — trading 18.6% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.40. Charles River Laboratories International's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Charles River Laboratories International (MIL:1CRL), the current LT-Debt-to-Total-Asset is 0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (MIL:1CRL) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of €143.90 is trading 18.6% above its estimated GF Value™ of €121.29.

Key valuation signals for MIL:1CRL:

LT-Debt-to-Total-Asset: 0.40
GF Value™: €121.29 vs. price of €143.90 (18.6% above fair value)
GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the MIL:1CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Charles River Laboratories International Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies RVTY QGEN ICLR TWST MEDP BLLN SHC VCYT RDNT ADPT TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Other Exchanges CRL:USA RV6:Germany

Address 251 Ballardvale Street, Wilmington, MA, USA, 01887

Website https://www.criver.com

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

70GF Score

Get the complete analysis for MIL:1CRL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.90

Price

€121.29

GF Value

View MIL:1CRL Analysis

See LT-Debt-to-Total-Asset data for all stocks →